FDMT लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

बेचें 104877 min ago

@ $27.97

जारी किया गया: 15 Feb 2024 @ 01:43

वापसी: -16.88%

पिछला सिग्नल: Feb 15 - 00:13

पिछला सिग्नल: खरीदें

वापसी: 2.04 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 01:30):

Stats
आज की मात्रा	317 415
औसत मात्रा	1.21M
बाजार मूल्य	1.19B
EPS	$0 ( 2024-03-20 )
अगली कमाई की तारीख	( $-0.730 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.01
ATR14	$0.0280 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-16	Bizily Scott	Sell	1 250	Stock Option (Right To Buy)
2024-04-16	Bizily Scott	Sell	500	Stock Option (Right To Buy)
2024-04-16	Bizily Scott	Buy	1 250	Common Stock
2024-04-16	Bizily Scott	Buy	500	Common Stock
2024-04-16	Bizily Scott	Sell	1 750	Common Stock

INSIDER POWER
31.08
Last 99 transactions
Buy: 3 571 023 \| Sell: 1 811 773

मात्रा सहसंबंध

लंबा: -0.14 (neutral)

छोटा: 0.80 (moderate)

Signal:(50.646) Neutral

4D Molecular सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
AFYA	0.848
RMCF	0.839
GOEV	0.826
NTCT	0.826
SLM	0.821
IMGN	0.818
TRMK	0.817
NDAQ	0.817
PRCT	0.816
LSXMA	0.816

10 सबसे अधिक नकारात्मक सहसंबंध
ISDX	-0.838
ZIONP	-0.827
TRHC	-0.826
NVSAU	-0.823
KSICU	-0.822
IOAC	-0.821
GRBK	-0.815
XFIN	-0.813
VRIG	-0.812
BRIVU	-0.81

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

4D Molecular सहसंबंध - मुद्रा/वस्त्र

0.38
( neutral )

0.31
( neutral )

0.00
( neutral )

0.38
( neutral )

-0.29
( neutral )

-0.32
( neutral )

4D Molecular वित्तीय

Annual	2023
राजस्व:	$20.72M
सकल लाभ:	$14.97M (72.26 %)
EPS:	$-2.58

FY	2023
राजस्व:	$20.72M
सकल लाभ:	$14.97M (72.26 %)
EPS:	$-2.58

FY	2022
राजस्व:	$3.13M
सकल लाभ:	$-751 000 (-24.00 %)
EPS:	$-3.12

FY	2021
राजस्व:	$18.04M
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-11.09

Financial Reports:

No articles found.

4D Molecular

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.